-
Alnylam Pharmaceuticals (ALNY) PT Raised to $500 at RBC Capital
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Amvuttra Survey Suggests 2Q Beat'
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'HQ Visit Makes Us More Positive About The Q'
-
Biotech sector Q1 earnings preview from RBC Capital Markets
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Incrementally More Positive on ALNY and Remain Buyers'
-
RBC on Alnylam Pharmaceuticals (ALNY): 'We Would Be Buyers Ahead Of Upcoming PDUFA Date'
-
RBC Capital on Alnylam Pharmaceuticals (ALNY): 'Our Expert Sees A Favorable Set-up'
-
RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $300 at RBC Capital
-
2Q24 U.S. biotech earnings preview
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $265 at RBC Capital, 'we remain buyers'
-
RBC Capital Positive on Alnylam Pharmaceuticals (ALNY): 'HELIOS-B Hits Convincingly Across the Board, Materially Exceeding Expectations'
-
RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY)
-
RBC Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY), 'HELIOS-B Likely To Hit The Primary Endpoint And We See Upside Post Recent Pullback'
-
UPDATE: RBC Capital Starts Alnylam Pharmaceuticals (ALNY) at Sector Perform
-
Medicines Company's (MDCO) Price Target Raised to $46 at RBC Following ALN-PCSsc Data
-
Morning Movers 02/18: (DIET) (CHCI) (TTGT) (APEI) (VMI) Higher; (RST) (CKH) Lower
-
Pre-Open Movers: Diebold (DBD) Surges On Takeover Bid, Thornburg Mortgage (TMA) Falls On Margin Calls

